Loading
A phase 3 trial of IBI363, Bevacizumab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer is a phase 3 interventional study registered as NCT07722494 by Innovent Biologics (Suzhou) Co. Ltd., with 550 participants planned, started 2026-07-31 and due to reach its primary completion in 2028-10-31. Interventions recorded: IBI363 + bevacizumab, Investigator's choice of therapy. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IBI363, Innovent Biologics, Colorectal cancer.
Shares IBI363, Innovent Biologics.
Shares IBI363, Innovent Biologics.
Shares Innovent Biologics, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares IBI363, Innovent Biologics.
Shares IBI363, Innovent Biologics.
Shares Innovent Biologics, Bevacizumab, Anti-angiogenic therapy.
Shares Innovent Biologics, Monoclonal antibodies, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/